Клинический разбор в общей медицине

В статье представлены современные подходы к иммунотерапии рака яичников. Рассмотрены основные виды иммунотерапии, включая моноклональные антитела, антитела, блокирующие иммунную контрольную точку, и клеточную иммунотерапию. Особое внимание в обзоре уделяется механизмам противоопухолевого действия иммунотерапевтических агентов. Освещены результаты некоторых предклинических исследований in vitro и in vivo и клинических исследований различных препаратов. Показаны дальнейшие перспективы применения указанных иммунотерапевтических подходов при лечении рака яичников.

Ключевые слова: рак яичников, иммунотерапия, моноклональные антитела, ингибиторы PD-1/PD-L1, клеточная иммунотерапия, TILs, CAR-T.

1. Guha P, Heatherton KR, O'Connell KP et al. Assessing the Future of Solid Tumor Immunotherapy. Biomedicines 2022;10(3):655. DOI: 10.3390/biomedicines10030655

2. Cancer Statistics Center. American Cancer Society Web site. Updated 2023. Available at: https://cancerstatisticscenter.cancer.org; accessed 11.10.2025.

3. Wang W, Liu JR, Zou W. Immunotherapy in Ovarian Cancer. Surg Oncol Clin N Am 2019;(28):447-64. DOI: 10.1016/j.soc.2019.02.002

4. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;(348):203-13. DOI: 10.1056/NEJMoa020177

5. Clarke B, Tinker AV, Lee CH et al. Intraepithelial T cells and prognosis in ovarian carcinoma: Novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009;(22):393-402. DOI: 10.1038/modpathol.2008.191

6. McAlpine JN, Porter H, Kobel M et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol 2012;(25):740-50. DOI: 10.1038/modpathol.2011.211

7. Боденко В.В., Ларькина М.С., Прач А.А. и др. Молекулярные мишени таргетной терапии злокачественных новообразований. Бюллетень сибирской медицины. 2024;23(2):101-13. DOI: 10.20538/1682-0363-2024-2-101-113

8. Frederick PJ, Straughn JMJr, Alvarez RD, Buchsbaum DJ. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecol Oncol 2009;(113):384-90. DOI: 10.1016/j.ygyno.2009.01.008

9. O’Brien TJ, Beard JB, Underwood LJ et al. The CA 125 gene: An extracellular superstructure dominated by repeat sequences. Tumour Biol 2001;(22):348-66. DOI: 10.1159/000050638

10. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;(10):942-9. DOI: 10.1038/nm1093

11. Noujaim AA, Schultes BC, Baum RP, Madiyalakan R. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13–evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm 2001;(16):187-203. DOI: 10.1089/10849780152389384

12. Berek J, Taylor P, McGuire W et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009;(27):418-25. DOI: 10.1200/JCO.2008. 17.8400

13. Holloway RW, Temkin SM, Gordon SW et al. A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with HiltonolÆ in Patients with Recurrent Platinum-Resistant Ovarian Cancer. Curr Oncol 2025;32(10):532. DOI: 10.3390/curroncol32100532

14. Maiorano BA, Maiorano MFP, Lorusso D, Maiello E. Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives. Cancers (Basel) 2021;13(17):4438. DOI: 10.3390/cancers13174438

15. Chen YL, Chang MC, Huang CY et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol 2012;(6):360-9. DOI: 10.1016/j.molonc.2011.11.010

16. Armstrong DK, White AJ, Weil SC et al. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 2013;(129):452-8. DOI: 10.1016/j.ygyno.2013.03.002

17. Kim KH, Jelovac D, Armstrong DK et al. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer. Gynecol Oncol 2016;(140):210-4. DOI: 10.1016/j.ygyno.2015.11.031

18. Konner JA, Bell-McGuinn KM, Sabbatini P et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: A phase I study. Clin Cancer Res 2010;(16):5288-95. DOI: 10.1158/1078-0432.CCR-10-0700

19. Vergote I, Armstrong D, Scambia G et al. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Ecacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients with Ovarian Cancer in First Platinum-Sensitive Relapse. J Clin Oncol 2016;(34):2271-8. DOI: 10.1200/JCO.2015.63.2596

20. Moore KN, Martin LP, O’Malley DM et al. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol 2016;(35):1112-8. DOI: 10.1200/JCO.2016.69.9538

21. Herzog TJ, Pignata S, Ghamande SA et al. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. Gynecol Oncol 2023;(170):300-8. DOI: 10.1016/j.ygyno.2023.01.003

22. Ab O, Whiteman KR, Bartle LM et al. IMGN853, a Folate Receptor-alpha (FRalpha)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRalpha-Expressing Tumors. Mol Cancer Ther 2015;(14):1605-13. DOI: 10.1158/1535-7163.MCT-14-1095

23. Borghaei H, O’Malley DM, Seward SM et al. Phase 1 study of IMGN853, a folate receptor alpha (FR)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors. J Clin Oncol 2015;(33):5558. DOI: 10.1200/jco.2015.33.15_suppl.5558

24. Moore KN, Oza AM, Colombo N et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol 2021;32(6):757-65. DOI: 10.1016/j.annonc.2021.02.017

25. Liu ZL, Chen HH, Zheng LL et al. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther 2023;8(1):198. DOI: 10.1038/s41392-023-01460-1

26. Burger RA, Brady MF, Bookman MA et al. Gynecologic Oncology Group Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-83. DOI: 10.1056/NEJM oa1104390

27. Perren TJ, Swart AM, Pfisterer J et al. ICON7 Investigators A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365 (26):2484-96. DOI: 10.1056/NEJMoa1103799

28. Pujade-Lauraine E, Hilpert F, Weber B et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30(18):LBA5002-LBA5002. DOI: 10.1200/jco.2012.30.18_ suppl.lba5002

29. Aghajanian C, Blank SV, Goff BA et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30(17):2039-45.

30. Randall LM, Burger RA, Nguyen H et al. Outcome differences in patients with stage IV epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab. Gynecol Oncol 2013;130(1):e33-e34.

31. Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 2018;18(2):91-104. DOI: 10.1038/nri.2017.112

32. Abers MS, Lionakis MS, Kontoyiannis DP. Checkpoint inhibition and infectious diseases: A good thing? Trends Mol Med 2019;25(12):1080-93. DOI: 10.1016/j.molmed.2019.08.004

33. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;(366):2455-65. DOI: 10.1056/NEJMoa1200694

34. Disis ML, Patel MR, Pant S et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial. J Clin Oncol 2015;(33):5509. DOI: 10.1200/jco.2015.33.15_suppl.5509

35. Varga A, Piha-Paul SA, Ott PA et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. J Clin Oncol 2015;(33):5510. DOI: 10.1200/jco.2015.33.15_suppl.5510

36. Hamanishi J, Mandai M, Ikeda T et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015;(33):4015-22. DOI: 10.1200/ JCO.2015.62.3397

37. Varga A, Piha-Paul S, Ott PA et al. Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE028. Gynecol Oncol 2019;(152):243-50. DOI: 10.1016/j.ygyno.2018.11.017

38. Matulonis UA, Shapira-Frommer R, Santin AD et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol 2019;(30):1080-7. DOI: 10.1093/annonc/mdz135

39. Veneziani AC, Gonzalez-Ochoa E, Alqaisi H et al. Heterogeneity and treatment landscape of ovarian carcinoma. Nat Rev Clin Oncol 2023;(20):820-42. DOI: 10.1038/s41571-023-00819-1

40. Johnson RL, Cummings M, Thangavelu A et al. Barriers to immunotherapy in ovarian cancer: metabolic, genomic, and immune perturbations in the tumour microenvironment. Cancers 2021;(13):6231. DOI: 10.3390/cancers13246231

41. Chardin L, Leary A. Immunotherapy in ovarian cancer: thinking beyond PD-1/ PD-L1. Front Oncol 2021;(11):795547. DOI: 10.3389/fonc.2021.795547

42. Шамова Т.В., Ситковская А.О., Ващенко Л.Н., Кечеджиева Э.Э. Адоптивная клеточная терапия: достижения последних лет. Южно-Pоссийский онкологический журнал. 2020;1(1):43-59. DOI: 10.37748/2687-0533-2020-1-1-4

43. Aoki Y, Takakuwa K, Kodama S et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 1991;(51):1934-9.

44. Kverneland AH, Pedersen M, Westergaard MCW et al. Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. Oncotarget 2020;(11):2092-105. DOI: 10.18632/oncotarget.27604

45. Amaria R, Knisely A, Vining D et al. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer 2024;12(2):e006822. DOI: 10.1136/jitc-2023-006822

46. Qin SS, Melucci AD, Chacon AC et al. Adoptive T cell therapy for solid tumors: pathway to personalized standard of care. Cells 2021;(10):808. DOI: 10.3390/cells10040808

47. Сорокина Л.Е., Незлина А.М., Красный А.М., Сухих Г.Т. Перспективы применения CAR-T-клеточной терапии при раке молочной железы: взгляд в будущее. Регенерация органов и тканей. 2024;2(2):10-23. DOI: 10.60043/2949-5938-2024-2-10-23

48. Cutri-French C, Nasioudis D, George E, Tanyi JL. CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now? Diagnostics (Basel) 2024;14(8):819. DOI: 10.3390/diagnostics14080819

49. Watanabe S, Arita M, Takahashi M et al. Effect of Lymphodepletion on Donor T Cells and the Role of Recipient Cells Persisting after Cytotoxic Treatments in Cancer Immunotherapies. Crit Rev Immunol 2017;(37):59-73. DOI: 10.1615/CritRevImmunol.2018019497

50. Kershaw MH, Westwood JA, Parker LL et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Pt 1. Clin Cancer Res 2006;(12):6106-15. DOI: 10.1158/1078-0432.CCR-06-1183

51. Haas AR, Tanyi JL, O’Hara MH et al. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Mol Ther 2019;(27):1919-29. DOI: 10.1016/j.ymthe.2019.07.015

52. Haas AR, Golden RJ, Litzky LA et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol Ther 2023;(31):2309-25. DOI: 10.1016/j.ymthe.2023.06.006

53. Tanyi J, Haas A, Aggarwal C et al. Phase I study of autologous T cells bearing fully-humanized chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers (314). Gynecol Oncol 2022;(166):S164-5. DOI: 10.1016/S0090-8258(22)01537-2